February 03, 2021 | Health Care | North America | Active

GW Pharmaceuticals / Jazz Pharmaceuticals: New Deal Insights


Marijuana stocks rallied on 3-Feb-21 after Jazz Pharmaceuticals agreed to a $7.2bn cash and stock acquisition of GW Pharmaceuticals, a drug company known for a cannabis-derived medication for epileptic seizures. Representing a 50% premium to GW’s previous day’s close, Jazz’s offer is for $220.00 per GW ADS through $200 in cash and $20 in Jazz shares ... Deal risks assessed in this research report: • Pushback from Congress on US cannabis policy reforms • Scrutiny of GW / Jazz pipeline overlaps • Hedging leakage from collar



How to Access this Report

Please contact us to request access to this report.


CONTACT US


Share this article



← RETURN TO RESEARCH

Back to top of page